Valeo Pharma Inc.
VPHIF
$0.0469
-$0.0471-50.11%
| 07/31/2024 | 04/30/2024 | 01/31/2024 | 10/31/2023 | 07/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -12.82% | 4.02% | 2.70% | 1.45% | 123.62% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -12.82% | 4.02% | 2.70% | 1.45% | 123.62% |
| Cost of Revenue | -14.25% | 18.43% | 15.35% | 13.86% | 161.23% |
| Gross Profit | -8.77% | -29.38% | -33.66% | -34.94% | 58.73% |
| SG&A Expenses | -36.11% | -1.71% | -2.08% | -3.35% | 8.42% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -23.11% | 9.95% | 7.92% | 6.29% | 66.26% |
| Operating Income | 65.35% | -38.65% | -25.72% | -20.95% | 19.03% |
| Income Before Tax | -36.71% | -20.37% | -9.81% | 13.62% | -4.63% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -36.71% | -20.37% | -9.81% | 2.73% | -4.63% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -36.71% | -20.37% | -9.81% | 2.73% | -4.63% |
| EBIT | 65.35% | -38.65% | -25.72% | -20.95% | 19.03% |
| EBITDA | 78.63% | -48.93% | -32.45% | -15.93% | 29.19% |
| EPS Basic | -16.99% | -2.10% | -3.14% | 14.10% | -1.17% |
| Normalized Basic EPS | 24.38% | -12.32% | -3.07% | 21.57% | -1.25% |
| EPS Diluted | -16.99% | -2.10% | -3.14% | 14.10% | -1.17% |
| Normalized Diluted EPS | 24.38% | -12.32% | -3.07% | 21.57% | -1.25% |
| Average Basic Shares Outstanding | 16.82% | 17.83% | 6.48% | 13.31% | 3.32% |
| Average Diluted Shares Outstanding | 16.82% | 17.83% | 6.48% | 13.31% | 3.32% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
